Ignite Creation Date:
2024-05-06 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06168890
Status:
COMPLETED
Last Update Posted:
2023-12-13
First Post:
2023-12-05
Brief Title:
Predictive Role of 11C Choline PETCT on Survival in Prostate Cancer Patients With Biochemical Failure
Sponsor:
IRCCS San Raffaele
Organization:
IRCCS San Raffaele
Study Overview
Official Title:
Predictive Role of 11C Choline PETCT on Survival in Prostate Cancer Patients With Biochemical Failure
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Several studies have shown that the PETCT study with Choline is of great use in the restaging of patients with prostate cancer who present a recurrence of biochemical disease following primary treatment Despite the large amount of literature in which the diagnostic accuracy of the method is highlighted in the identification of the recurrence of prostatic disease both in the case of local recurrence lymph node recurrence and metastatic disease there are to date no studies that evaluate whether PET CT with choline may predict survival in patients radically treated for prostate cancer The aim of the study is to evaluate the predictive role of choline PETCT on the survival of patients with biochemical recovery of the disease during hormonal therapy
This retrospective study will include adult patients affected by prostate cancer with biochemical recurrence of the disease following radical prostatectomy treatment and undergoing hormonal therapy who underwent between 2004 and 2007 a PETCT study with choline for the restaging of their disease
The expected result is to establish how PETCT with Choline can predict survival in patients who develop a biochemical recurrence of the disease during hormonal therapy If this result is confirmed PETCT with Choline could be even more useful in the follow-up of patients radically treated for prostate cancer to plan the best therapeutic approach
This retrospective study will include adult patients affected by prostate cancer with biochemical recurrence of the disease following radical prostatectomy treatment and undergoing hormonal therapy who underwent between 2004 and 2007 a PETCT study with choline for the restaging of their disease
The expected result is to establish how PETCT with Choline can predict survival in patients who develop a biochemical recurrence of the disease during hormonal therapy If this result is confirmed PETCT with Choline could be even more useful in the follow-up of patients radically treated for prostate cancer to plan the best therapeutic approach
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None